GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kobo Biotech Ltd (BOM:531541) » Definitions » Debt-to-Equity

Kobo Biotech (BOM:531541) Debt-to-Equity : N/A (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Kobo Biotech Debt-to-Equity?

Kobo Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Kobo Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Kobo Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kobo Biotech's Debt-to-Equity or its related term are showing as below:

BOM:531541' s Debt-to-Equity Range Over the Past 10 Years
Min: -25.9   Med: -1.34   Max: 28.69
Current: -1.07

During the past 13 years, the highest Debt-to-Equity Ratio of Kobo Biotech was 28.69. The lowest was -25.90. And the median was -1.34.

BOM:531541's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs BOM:531541: -1.07

Kobo Biotech Debt-to-Equity Historical Data

The historical data trend for Kobo Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kobo Biotech Debt-to-Equity Chart

Kobo Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.53 -2.85 -2.43 -1.15 -1.09

Kobo Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A -1.09 N/A -1.07 N/A

Competitive Comparison of Kobo Biotech's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Kobo Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobo Biotech's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kobo Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kobo Biotech's Debt-to-Equity falls into.



Kobo Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kobo Biotech's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Kobo Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kobo Biotech  (BOM:531541) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Kobo Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kobo Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Kobo Biotech (BOM:531541) Business Description

Traded in Other Exchanges
N/A
Address
Saki Vihar Road, Unit 104, HYDE Park, Opp. Ansa Industrial Estate, Andheri (East), Mumbai, MH, IND, 400 072
Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.

Kobo Biotech (BOM:531541) Headlines

No Headlines